Ciprofloxacin Therapy Research Articles

Randomised Comparison of Oral Ciprofloxacin vs Standard Parenteral Therapy in the Treatment of Complicated Urinary Tract Infections

Randomised Comparison of Oral Ciprofloxacin vs Standard Parenteral Therapy in the Treatment of Complicated Urinary Tract Infections

In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.

Cefoxitin, cefotetan, cefmetazole, ceftizoxime, imipenem plus cilastatin, ampicillin plus sulbactam and clindamycin alone or combined with gentamicin, ciprofloxacin, ofloxacin or aztreonam were compared in the therapy of intraabdominal infection in mice caused by Escherichia coli in combination with either Bacteroides fragilis or Bacteroides thetaiotaomicron. Mortality in the control group was 45%, and no animal receiving either imipenem, gentamicin, ciprofloxacin, ofloxacin or aztreonam died. Mortality in mice receiving cefoxitin, cefotetan, cefmetazole, or ceftizoxime was below 7% (P < 0.05%) and mortality following treatment with ampicillin-sulbactam was 23-27% (P > 0.05). The abscesses were examined ten days after inoculation. No abscesses were observed in mice treated with clindamycin or imipenem. Therapy with gentamicin, ciprofloxacin, ofloxacin, aztreonam or ceftizoxime alone did not prevent abscess formation by both Bacteroides sp. A significant reduction in abscess formation and number of E. coli and B. fragilis was observed with combination therapy of clindamycin with either ciprofloxacin, ofloxacin, aztreonam, or gentamicin and single agent therapy with either imipenem, cefoxitin, cefotetan, cefmetazole and ampicillin-sulbactam alone. However, cefotetan and cefmetazole did not reduce abscess formation or the number of B. thetaiotaomicron. These in-vivo data confirm the in-vitro activity of these antimicrobials.

Ciprofloxacin Versus Trimethoprim-Sulfamethoxazole: Treatment of Community-Acquired Urinary Tract Infections in a Prospective, Controlled, Double-Blind Comparison

In this study, we determined the safety and efficacy of the treatment of adults with urinary tract infection with ciprofloxacin hydrochloride (250 mg twice daily for 10 days) in comparison with trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily for 10 days). Patients with signs and symptoms of urinary tract infection were randomized to receive ciprofloxacin (98 women and 5 men) or trimethoprim-sulfamethoxazole (92 women and 8 men). The success rate of therapy was 91% for both treatment arms of the study. Among seven failures after ciprofloxacin therapy, three were due to relapse of infection and two to side effects that necessitated a change in medication; in addition, two patients had persistent symptoms and required hospitalization. Among the six failures associated with trimethoprim-sulfamethoxazole therapy, four were due to relapse, one to persistence of infection, and one to a side effect that necessitated a change in medication. Among the patients treated with trimethoprim-sulfamethoxazole, 32% had mild or moderate adverse reactions; in comparison, 17% of the ciprofloxacin-treated patients had adverse reactions (P = 0.026). For the treatment of urinary tract infection in adult patients in this study, ciprofloxacin and trimethoprim-sulfamethoxazole were equally effective, but ciprofloxacin was associated with fewer adverse reactions.

Fulminant Hepatic Failure Possibly Related to Ciprofloxacin

To report a case of hepatic failure in a patient who was receiving oral ciprofloxacin. Case reports, review articles, and relevant laboratory studies identified by MEDLINE. Data were abstracted from pertinent published sources by one author and reviewed by the remaining authors. A 66-year-old man was admitted for hip arthroplasty and developed fulminant hepatic failure during oral ciprofloxacin therapy. Ciprofloxacin was started on postoperative day 13 for treatment of a urinary tract infection. Over the next three days he became confused and hypoglycemic. His prothrombin time increased to greater than 90 s. Serum aspartate aminotransferase and alanine aminotransferase concentrations were markedly elevated. The patient died on postoperative day 20. Postmortem examination of the liver revealed extensive centrilobular necrosis. A skin biopsy was consistent with a drug reaction. It is unknown whether the patient had received a quinolone compound in the past or had a history of exposure to hepatotoxins. It cannot be concluded that ciprofloxacin directly caused hepatic failure in this patient. It is possible that the drug evoked a hypersensitivity reaction or exacerbated a preexisting hepatotoxicity. A detailed patient history and evaluation of hepatic function should be obtained prior to initiating ciprofloxacin therapy. A nonquinolone antimicrobial may be a safer alternative for patients with hepatic dysfunction.

Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea

Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea

Intravenous Ciprofloxacin Therapy in Respiratory Infections

DOI: http://dx.doi.org/10.5915/24-1-15458 Of the quinolone class of antimicrobials, only intravenous (IV) ciprofloxacin is currently available for treatment of various bacterial infections. Pathogens causing pneumonia in otherwise healthy adult patients may differ from those found in elderly patients, nursing home residents, alcoholics, and in individuals with debilitating diseases. Nosocomial pneumonias typically involve Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. Aspiration pneumonia in the community most often involves anaerobes, but in the hospital S. aureus and Gram-negative organisms are commonly found. Based on these clinical and microbiological issues, a comparative evaluation of sequential IV and oral (PO) ciprofloxacin versus other antibiotics were reviewed and the results are summarized in this article. The focus is on the role of sequential intravenous/oral ciprofloxacin in the treatment of lower respiratory tract injection. Presented at the lMA 24th Annual Convention Long Island, New York, July 1991

Recent developments in the treatment of sexually transmitted diseases

Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant Neisseria gonorrhoeae identification of Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and the realization that the urethritis syndrome is often associated with multiple pathogens. There is currently no monotherapy that eradicates all STD pathogens. The role of fluoroquinolones in the treatment of STDs is still evolving. The investigational agent, temafloxacin, has good activity against gonococci, nongonococcal organisms, and, unlike other quinolones, against Bacteroides fragilis and other anaerobes. Norfloxacin, ciprofloxacin, enoxacin, ofloxacin, and temafloxacin single-dose therapy have demonstrated clinical efficacy for gonococcal infections in non-comparative and comparative trials, including bacterial eradication of isolates resistant to other agents.

Susceptibility of Brucella melitensis to the New Fluoroquinolone CI-960

In vitro antibacterial activity of the new fluoroquinolone CI-960 was tested against 139 strains of Brucella melitensis, isolated from 138 patients in a major tertiary care referral centre. Seven percent of the strains were inhibited by 0.06 mg/L and 99% by 0.12 mg/L of CI-960. Five other fluoroquinolones tested had comparable or slightly higher minimum inhibitory concentration values, inhibiting the growth of 138 of the 139 isolates at 0.25 to 0.5 mg/L One isolate, which had previously developed resistance during ciprofloxacin therapy, showed cross-resistance to CI-960 and other fluoroquinolones.

A Randomized Study of Ciprofloxacin versus Ceftriaxone in the Treatment of Nursing Home‐Acquired Lower Respiratory Tract Infections

To compare the efficacy and safety of ciprofloxacin and ceftriaxone in patients with nursing home-acquired lower respiratory tract infections requiring initial hospitalization. Prospective, randomized trial. Extended care nursing homes affiliated with a teaching hospital. Fifty patients aged 60 years or older with normal or mildly impaired renal function admitted to the hospital for treatment of lower respiratory tract infections. Twenty-four patients received initial therapy with intravenous ciprofloxacin, 200 mg every 12 hours (19 patients) or 400 mg every 12 hours (5 patients) during the acute phase followed by 750 mg orally every 12 hours during the convalescence phase. Twenty-six patients received initial therapy with intravenous ceftriaxone, 2 g every 24 hours during the acute phase followed by 1 g administered intramuscularly every 24 hours during the convalescent phase. The total duration of therapy was 14 days. Successful outcome was defined as resolution or marked improvement in clinical signs and symptoms of lower respiratory tract infection upon completion of the treatment course. Twelve (50%) of the ciprofloxacin-treated and 14 (54%) of ceftriaxone-treated patients had successful outcomes. Recurrent oropharyngeal aspiration was the reason for treatment failure in most patients refractory to either antibiotic. Mortality during therapy was 8% in each group. From 21 satisfactory sputum specimens collected, S. pneumoniae was the most common isolate, followed by H. influenzae and other Gram-negative bacteria. Ciprofloxacin therapy was well tolerated; ceftriaxone therapy was discontinued in two patients (8%) due to adverse reactions (intramuscular pain and drug fever). Sequential intravenous/oral ciprofloxacin appears to be as safe and effective as sequential intravenous/intramuscular ceftriaxone. The optimal dosage of intravenous ciprofloxacin in this patient population appears to be 400 mg every 12 hours; however, additional clinical and pharmacokinetic studies with this regimen are warranted.

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied. Low to moderate levels of ciprofloxacin resistance developed in each case. Each set of pretherapy ciprofloxacin-susceptible, during-therapy ciprofloxacin-resistant, and posttherapy ciprofloxacin-susceptible isolates were shown to be genotypically related by using a radiolabeled epidemiological gene probe. All ciprofloxacin-resistant isolates were found to have altered susceptibilities to both nalidixic acid and various chemically unrelated antibiotics. Analysis of possible resistance mechanisms showed that the strains had altered outer membrane protein or lipopolysaccharide profiles. Complementation of possible DNA gyrase mutations with a plasmid-borne, wild-type Escherichia coli gyrA gene indicated that altered DNA gyrase was at least partly responsible for ciprofloxacin resistance in all strains tested. Attempts to generate ciprofloxacin-susceptible revertants in vitro showed that in some strains reversion was rapid in the absence of ciprofloxacin, while in other strains it was not possible to generate revertants. These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.

Refractory Chronic Bacterial Prostatitis: A Re-Evaluation of Ciprofloxacin Treatment After a Median Followup of 30 Months

A total of 16 men suffering from refractory chronic bacterial prostatitis caused by Escherichia coli was treated with ciprofloxacin for 4 weeks. After a median followup of 30 months (range 21 to 36 months) 10 of the 16 patients were considered cured as judged by bacteriological results and clinical symptoms. In 2 men a second ciprofloxacin regimen obviously showed success also. In 2 patients ciprofloxacin therapy failed and in 2 therapy had to be discontinued due to side effects of the central nervous system.

Fluoroquinolones in the treatment of cystic fibrosis: A critical appraisal

While the appropriate usage of antibiotics in cystic fibrosis patients is still a matter of debate, the introduction of oral antipseudomonal antibiotics such as fluoroquinolones represents an eagerly awaited addition to the therapeutic armamentarium. Ciprofloxacin is the single agent most often studied and used in this population for treatment of pulmonary exacerbations. Altered pharmacokinetics of fluoroquinolones have been described in cystic fibrosis patients as for other drugs, and a higher dosage than usual is recommended. Open clinical trials have shown good efficacy of ciprofloxacin in acute infection. A few comparative trials have demonstrated that ciprofloxacin is as effective clinically as conventional intravenous agents. As with other agents, a lack of correlation between clinical improvement and bacteriologic evaluation has been observed. Ciprofloxacin (and possibly ofloxacin) are considered useful alternatives to parenteral agents in therapy of cystic fibrosis patients older than 18 years of age with exacerbations of pulmonary infection. Intermittent therapy with ciprofloxacin alternating with other conventional treatment appears to be a rational approach; clinical trials evaluating the alternation of fluoroquinolones with intravenous anti-pseudomonal therapy are necessary. Considering the potential for emergence of resistance and the not completely elucidated implication of increasing MICs during ciprofloxacin therapy, the duration of treatment should be limited to 2 to 4 weeks. In older children (12 to 18 years old), ciprofloxacin provides an alternative to intravenous agents when clinically justifiable. In view of the possibility of fluoroquinolone associated-arthropathy in younger children, ciprofloxacin should be used judiciously when no alternative agents are available or in life-threatening situations.

Failure of Ciprofloxacin to Eradicate Convalescent Fecal Excretion after Acute Salmonellosis: Experience during an Outbreak in Health Care Workers

To determine the efficacy of ciprofloxacin therapy in eradicating convalescent fecal excretion of salmonellae after acute salmonellosis. Randomized, placebo-controlled, double-blind trial of ciprofloxacin, with prospective follow-up of nonparticipants. An acute care community hospital experiencing an outbreak of salmonellosis. Twenty-eight health care workers developed acute infection with Salmonella java; 15 participated in a placebo-controlled trial of ciprofloxacin, beginning on day 9 after infection. Eight patients were randomly assigned to receive ciprofloxacin, 750 mg, and 7 patients to receive placebo; both were administered orally twice daily for 14 days. Nonparticipants who received therapy were placed on the same ciprofloxacin regimen. Study participants had follow-up stool cultures every 3 days initially and then weekly for 3 weeks; nonparticipants were followed until three consecutive cultures were negative. All eight ciprofloxacin recipients showed eradication of S. java from stool cultures within 7 days of beginning therapy (compared with 1 of 7 placebo recipients), and their stool cultures remained negative up to 14 days after discontinuing therapy (P less than 0.01). However, 4 of 8 relapsed; their stool cultures became positive between 14 and 21 days after therapy. In addition, 3 of 3 hospitalized patients treated with ciprofloxacin who did not participate in the controlled trial also relapsed. Thus, the total relapse rate was 7 of 11 (64%; 95% CI, 31% to 89%). In 4 of these 7 patients, relapse was associated with a longer duration of fecal excretion of salmonellae than that of the placebo group. Relapse could not be explained on the basis of noncompliance, development of resistance, or presence of biliary disease. Despite its excellent antimicrobial activity against salmonellae and its favorable pharmacokinetic profile, ciprofloxacin at a dosage of 750 mg orally twice daily had an unacceptably high failure rate in patients with acute salmonellosis and may have prolonged fecal excretion of salmonellae. The late occurrence of relapses indicates the need to obtain stool cultures up to 21 days after therapy to document fecal eradication in acute salmonellosis.

Uptake of 3H-norfloxacin in methicillin-resistant Staphylococcus aureus

To examine the possibility of a proton-motive efflux pump for quinolones in highly quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA), we studied 3H-norfloxacin uptake in two quinolone-resistant and two quinolone-sensitive strains of MRSA whose gyrA region surrounding amino acid codons 84 and 85 had been sequenced. Two strains were related (one sensitive and one resistant) in that both were recovered from a single patient, one before (sensitive) and one after (resistant) ciprofloxacin therapy. Drug uptake was assessed in four separate experiments running triplicate bacterial suspensions with radiolabeled drug added at time = 0. Sampling was performed in 10 min increments up to 50 min by a vacuum filtration method. The ionic uncoupler, carbonyl cyanide m-chlorophenylhydrazone (CCCPH), was added at 40 min to test inhibition of a pump mechanism. The results demonstrated no statistically significant differences in uptake between the sensitive and resistant groups, and the uptake patterns were similar. CCCPH also induced an equivalent surge, or enhanced uptake among these strains, rendering an energy-dependent efflux pump an unlikely contributor to the high levels of resistance seen in our strains. Our findings support parallel studies done on these isolates that implicate mutational changes at amino acid codon 84 and/or codon 85 in the gyrA gene as an explanation for high-level quinolone resistance (MIC to ciprofloxacin greater than or equal to 16 mg/L) in MRSA.

Acute Renal Failure Due to Ciprofloxacin

Acute renal failure developed in three patients within a few days of starting ciprofloxacin hydrochloride therapy. An allergic interstitial nephritis was suggested by fever and eosinophiluria in one patient and by erythema multiforme in another. A kidney biopsy specimen confirmed this diagnosis in one patient. Renal function improved shortly after withdrawal of the drug in all three patients. Literature survey revealed an additional three patients with a similar complication. Allergic manifestations, such as fever or rash, were a feature in most reported cases. In view of this potential complication, renal function should be closely monitored in patients receiving ciprofloxacin therapy, especially if other potentially nephrotoxic drugs are prescribed concomitantly.

Update on Quinolone Drug Interactions: Sucralfate, theophylline, and antacids can affect the bioavailability of quinolones.

Concurrent administration of both ciprofloxacin and norfloxacin with sucralfate leads to a decrease in quinolone bioavailability. It is unknown whether this decrease is clinically significant because studies have focused primarily on pharmacokinetics and not therapeutic outcomes. A reasonable recommendation may be to avoid using sucralfate and norfloxacin concurrently, or avoid administration of norfloxacin and ciprofloxacin within two hours of sucralfate administration. Magnesium- and aluminum-containing antacids may also interfere with quinolone absorption. Calcium carbonate and H2 receptor antagonists do not appear to interact with quinolones and may be considered as an alternative to sucralfate or magnesium- and aluminum-containing antacids when quinolones are administered. Concurrent administration of ciprofloxacin and theophylline may precipitate theophylline toxicity if not monitored carefully. Some clinicians recommend a 30% empiric reduction in theophylline dosage when ciprofloxacin therapy is initiated. Because the drug interaction is not completely predictable, the patient's theophylline levels should be monitored and signs and symptoms of toxicity noted, adjusting the dose as needed. Decreased theophylline clearance may persist for as long as five days following discontinuation of ciprofloxacin. Some potential for slight increases in serum theophylline concentrations secondary to norfloxacin administration may exist. However, it is unlikely to be clinically significant, based on currently available information.

Oral clindamycin and ciprofloxacin therapy for diabetic foot infections: a retraction.

Oral clindamycin and ciprofloxacin therapy for diabetic foot infections: a retraction.

Allergic Nephropathy Associated With Ciprofloxacin

We report a case of ciprofloxacin-related allergic tubulointerstitial nephritis, which manifested as nonoliguric renal failure, eosinophilia, and eosinophiluria. Our patient responded to discontinuation of ciprofloxacin therapy and oral administration of a brief course of corticosteroids. Although rare, allergic tubulointerstitial nephritis apparently can be caused by ciprofloxacin therapy. Clinicians should be aware of this entity.

Seizure with Ciprofloxacin and Theophylline Combined Therapy

Ciprofloxacin has been reported to cause theophylline toxicity by inhibiting theophylline metabolism. A 93-year-old woman without a known seizure history, while on ciprofloxacin and theophylline combined therapy, experienced a grand mal seizure. Her serum theophylline concentration at the time was 20 micrograms/mL. On previous occasion of theophylline toxicity, she had a serum theophylline concentration of 27 micrograms/ml but the patient did not experience any seizure. Several reports suggest that the combination of theophylline and ciprofloxacin has an additive inhibitory effect on gamma-aminobutyric acid (GABA) sites. Inhibition of the binding of GABA to its receptor sites has been related to the convulsant effects of other drugs. The seizure in our patient may have been caused by altered pharmacokinetics and pharmacodynamics brought about by combined therapy of theophylline and ciprofloxacin.